Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

An estimated 15–20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer. Lapatinib, a reversible epidermal g...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Denis M., Conlon, Neil T., Kannan, Srinivasaraghavan, Verma, Chandra S., Eli, Lisa D., Lalani, Alshad S., Crown, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628314/
https://www.ncbi.nlm.nih.gov/pubmed/31141894
http://dx.doi.org/10.3390/cancers11060737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628314/
https://www.ncbi.nlm.nih.gov/pubmed/31141894
http://dx.doi.org/10.3390/cancers11060737

Ejemplares similares